Abstract: Intralesional injection is an antitumor therapy in which the injected agents shrink the tumor directly and stimulate a systemic immune response to kill noninjected tumors（namely bystander effect）. Talimogene laherparepvec， an intralesional injection agent， was approved by U.S. Food and Drug Administration on October， 2015 for the local treatment of unresectable cutaneous， subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery， inspiring more attention to this treatment method. In the current review， we summarize a series of intralesional injection agents（including cytokines， plasmid， oncolytic virus， etc.） for melanoma and propose future study in this field.